Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989798 | 1.00 | TAAR1 (0.62) | TAAR1ACHESTAT3GRIA4CYP1A2 | |
| Hydrochloric Acid SCHEMBL5878048 | 0.98 | TAAR1 (0.60) | TAAR1ACHESTAT3GRIA4CYP1A2 | |
| SCHEMBL3006604 | 0.89 | TAAR1 (0.75) | TAAR1TDP1 | |
| Hydrochloric Acid SCHEMBL6564727 | 0.87 | TAAR1 (0.71) | TAAR1TDP1 | |
| SCHEMBL5146825 | 0.81 | ACHE (0.46) | TAAR1ACHESTAT3GRIA4CYP1A2 | |
| SCHEMBL17504534 | 0.81 | TAAR1 (0.42) | TAAR1ACHESTAT3GRIA4CYP1A2 | |
| Hydrochloric Acid SCHEMBL5877955 | 0.80 | TAAR1 (0.62) | TAAR1TDP1 | |
| SCHEMBL4527843 | 0.80 | TAAR1 (0.62) | TAAR1ACHEGRIA4TDP1 | |
| SCHEMBL20425554 | 0.78 | TAAR1 (0.60) | TAAR1CYP1A2CYP2A6ALOX5MAOA | |
| SCHEMBL21286098 | 0.78 | TAAR1 (0.60) | TAAR1CYP1A2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191721-A2 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM ALKENES BY CASCADE BIOTRANSFORMATION INVOLVING 1,2-METHYL SHIFT | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-10-05 | — | — | WO | disclosed |
| US-20220168362-A1 | BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID | SYNLOGIC, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11060073-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210180033-A1 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC OPERATING COMPANY, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20190160115-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | SYNLOGIC, INC. | 2019-05-30 | — | — | US | disclosed |
| US-20170253862-A1 | Bacteria Engineered to Treat Diseases Associated with Hyperammonemia | SYNLOGIC, INC. | 2017-09-07 | — | — | US | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160115-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | PDCD1, CD274, PDCD4 | TAAR1 3796/4885ACHE 2963/4885STAT3 127/4885 |
| US-20170253862-A1 | Bacteria Engineered to Treat Diseases Associated with Hyperammonemia | ASS1, AGXT, OAT | TAAR1 1400/4885ACHE 3871/4885STAT3 1522/4885 |
| US-11060073-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | ASS1, AGXT, OAT | TAAR1 1400/4885ACHE 3871/4885STAT3 1522/4885 |
| US-20210180033-A1 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | ASS1, AGXT, OAT | TAAR1 1400/4885ACHE 3871/4885STAT3 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.